GenSight Biologics SA stock analysis
GenSight Biologics SA (0RIM) Share Price & Analysis
0RIM Stock Chart & Stats
- Day’s Range
- EUR 0.08 - EUR 0.08
- 52-Week Range
- EUR 0.06 - EUR 0.15
- Previous Close
- EUR 0.08
- Volume
- N/A
- Average Volume (3M)
- 25.00K
- Market Cap
- EUR 18.71M
- Enterprise Value
- EUR 29.15M
- Total Cash (Recent Filing)
- EUR 1.67M
- Total Debt (Recent Filing)
- EUR 12.84M
- Price to Earnings (P/E)
- ―
- Beta
- 0.50
- Next Earnings
- Mar 19, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Focused Therapeutic Pipeline
The company is concentrated on specialized gene-therapy and optogenetics approaches for severe retinal disorders, giving its development strategy a clear therapeutic focus. If clinical and regulatory progress continues, these programs could create meaningful value through differentiated treatments rather than broad, unfocused research activity.
Lower Debt Burden
Debt reduction is a constructive balance-sheet development because it can lower financing pressure and improve flexibility relative to the company’s prior position. Although solvency remains constrained, reducing borrowings may help preserve resources for advancing the pipeline and managing near-term obligations.
Improved Cash-burn Trend
The smaller operating cash outflow indicates some improvement in cash discipline or spending intensity compared with the prior year. Sustaining and extending this trend would lengthen available funding capacity and reduce the pace at which external capital is needed to support ongoing development.
Bears Say
Severe Revenue Collapse
The near-total revenue collapse demonstrates that the business currently has very limited commercial scale and weak revenue visibility. Without a durable recovery, the company will have less internally generated funding for research and development, leaving future progress heavily dependent on financing or successful product advancement.
Persistent Unprofitability
Recurring operating and net losses show that the company remains far from breakeven and has not yet converted its development activities into sustainable earnings. Continued losses can consume capital, restrict strategic flexibility, and increase the financial burden of bringing its therapies toward commercialization.
Negative Shareholders’ Equity
Persistent negative equity is a significant solvency weakness because liabilities exceed the recorded asset base and the capital structure has limited financial resilience. This condition can increase reliance on external funding, constrain investment choices, and make the company more vulnerable if capital markets become less accessible.
GenSight Biologics SA News
GenSight’s REVISE Trial Moves Forward: What Lumevoq’s New Dose-Range Study Means for Investors
GenSight Biologics ($DE:G49N) announced an update on their ongoing clinical study. The REVISE study, officially titled “A Dose-ranging Randomized, Open-label Study Evaluating the Effect of Bilateral Intravitreal Injection of GS010
0RIM FAQ
What was GenSight Biologics SA’s price range in the past 12 months?
What is GenSight Biologics SA’s market cap?
When is GenSight Biologics SA’s upcoming earnings report date?
How were GenSight Biologics SA’s earnings last quarter?
Is GenSight Biologics SA overvalued?
Does GenSight Biologics SA pay dividends?
What is GenSight Biologics SA’s EPS estimate?
How many shares outstanding does GenSight Biologics SA have?
What happened to GenSight Biologics SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of GenSight Biologics SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
GenSight Biologics SA
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Laurence Rodriguez
- Employees
- 18
- Website
- www.gensight-biologics.com
- Address
- 74, rue du Faubourg Saint-Antoine, Paris, IF, 75012, FR
GenSight Biologics SA (0RIM) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 5 | 12 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 1 | 0 | 11 |








